Tumores colorrectales
Desarrollo y puesta en marcha de una estrategia de medicina personalizada en pacientes con cáncer colorectal.
Grupo consolidado en el manejo de pacientes con cáncer colorectal que reúne y coordina en un equipo multidisciplinar toda la investigación básica, clínica y traslacional realizada en la Clínica Universidad de Navarra y en el Centro para la Investigación Médica Aplicada (CIMA) en torno al desarrollo e innovación terapeutica en el cáncer de colon.
Alsina, M, Villacampa, G, de Andrea, C, Vivancos, A, Ponz-Sarvise, M, Arrazubi, V, Jimenez-Fonseca, P, Diez, M, Sanz-Garcia, E, Martínez, E, Guardeño, R, Calvo, M, Bugés, C, Longo, F, Navarro, V, García-Galea, E, Gros, A, Ochoa, MC, Lopez-Janeiro, A, Sanchez-Gregorio, S, Herrero, C, Labiano, I, Vila-Casadesús, M, López, D, Alexandru, R, Muñoz, S, Tabernero, J, Melero, I
"A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study".
Clin. Cancer Res.. 31(14): 2890 - 2898. 2025. [doi:10.1158/1078-0432.CCR-25-0369]
Frühbeck, G, Criado, S, Gómez-Ambrosi, J, Ramírez, B, Becerril, S, Rodríguez, A, Neira, G, Salmón-Gómez, L, Valentí, V, Moncada, R, Baixauli, J, Silva, C, Catalán, V
"Increased IL-36? in visceral adipose tissue as a key mediator of obesity-driven inflammation in colon cancer".
J. Mol. Med.. 103(6): 699 - 711. 2025. [doi:10.1007/s00109-025-02546-9]
Ortego, M, Arrizibita, O, Martinez-Lage, A, Atienza, AV, Gigli, LA, Ruiz, O, Subtil, JC, Zabalza, M, Valentí, V, Tortajada, A, Hidalgo, MJ, Sayar, O, Rodriguez, J
"Neoadjuvant Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma: Long-Term Results and Statistical Algorithm to Predict Individual Risk of Relapse".
Cancers. 17(9): 1530. 2025. [doi:10.3390/cancers17091530]
Ko, AH, Oh, D, Lau, J, Mhatre, SK, Ci, B, Machado, R, Li, S, Bretscher, MT, Reyes-Rivera, I, Zhu, JW, Zhang, XS, Patel, J, Psioda, MA, Ponz-Sarvise, M
"Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial.".
Clin. Pharmacol. Ther.. 117(4): 1021 - 1029. 2025. [doi:10.1002/cpt.3528]
Xu, JH, Pham, MD, Corbo, V, Ponz-Sarvise, M, Oni, T, Oehlund, D, Hwang, CI
"Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology".
Exp. Mol. Med.. 57(1): 50 - 58. 2025. [doi:10.1038/s12276-024-01378-w]
Oyon, D, Lopez-Pascual, A, Castello-Uribe, B, Uriarte, I, Orsi, G, Llorente, S, Elurbide, J, Adan-Villaescusa, E, Valbuena-Goiricelaya, E, Irigaray-Miramon, A, Latasa, MU, Martinez-Perez, LA, Bonetti, LR, Prosper, F, Ponz-Sarvise, M, Vicent, S, Pineda-Lucena, A, Ruiz-Clavijo, D, Sangro, B, Larracoechea, UA, Tian, TV, Casadei-Gardini, A, Amat, I, Arechederra, M, Berasain, C, Urman, JM, Avila, MA, Fernandez-Barrena, MG
"Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma".
J. Exp. Clin. Cancer Res.. 44(1): 13. 2025. [doi:10.1186/s13046-024-03268-5]
Siena, S, Raghav, K, Masuishi, T, Yamaguchi, K, Nishina, T, Elez, E, Rodriguez, J, Chau, I, Di Bartolomeo, M, Kawakami, H, Suto, F, Koga, M, Inaki, K, Kuwahara, Y, Takehara, I, Barrios, D, Kobayashi, K, Grothey, A, Yoshino, T
"HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 (vol 15, 10213 , 2024)".
Nat. Commun.. 16(1): 704. 2025. [doi:10.1038/s41467-025-56170-9]
Silva-Pilipich N, Beloki U, Apaolaza P, Igea A, Salaberry L, Prats-Mari L, Rovira E, Ondiviela M, Gorraiz M, Lasarte JJ, Vanrell L, Smerdou C
"Targeting PD-1(+) T cells with small-format immunocytokines enhances IL-12 antitumor activity.".
Mol. Ther.. 33(1): 297 - 316. 2025. [doi:10.1016/j.ymthe.2024.11.027]
Hangiu O, Navarro R, Frago S, Rubio-Pérez L, Tapia-Galisteo A, Díez-Alonso L, Gómez-Rosel M, Silva-Pilipich N, Vanrell L, Smerdou C, Howard KA, Sanz L, Álvarez-Vallina L, Compte M
"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.".
Front. Immunol.. 15: 1494206 - 1494206. 2025. [doi:10.3389/fimmu.2024.1494206]
|